SECOND AMENDMENT TO THE SUPPLY AGREEMENTSupply Agreement • November 5th, 2014 • Alliqua BioMedical, Inc. • Surgical & medical instruments & apparatus
This Second Amendment (“Second Amendment”) to the Supply Agreement dated November 14, 2013 (as amended by the First Amendment to the Supply Agreement dated April 10, 2014) (collectively the Supply Agreement and First Amendment hereinafter the “Agreement”), is effective as of September 26, 2014 (the “Second Amendment Effective Date”), by and between Anthrogenesis Corporation, a Delaware corporation doing business as Celgene Cellular Therapeutics (“CCT”), and Alliqua BioMedical, Inc., a Delaware corporation (formerly Alliqua, Inc., a Florida corporation) (“Alliqua”). Alliqua and CCT may each be referred to as a “Party” or collectively be referred to as the “Parties”.
FIRST AMENDMENT TO THE LICENSE, MARKETING AND DEVELOPMENT AGREEMENTLicense, Marketing and Development Agreement • November 5th, 2014 • Alliqua BioMedical, Inc. • Surgical & medical instruments & apparatus
This First Amendment (“First Amendment”) to the License, Marketing and Development Agreement dated November 14, 2013 (the “Agreement”) is effective as of September 26, 2014 (the “First Amendment Effective Date”), by and between Anthrogenesis Corporation, a Delaware corporation doing business as Celgene Cellular Therapeutics (“CCT”), and Alliqua BioMedical, Inc., a Delaware corporation (formerly Alliqua, Inc., a Florida corporation) (“Alliqua”). Alliqua and CCT may each be referred to as a “Party” or collectively be referred to as the “Parties”.
